Serum, Pleural Effusion, and Ascites CA-125 Levels in Ovarian Cancer and Nonovarian Benign and Malignant Diseases: A Comparative Study

Topalak, Ömer; Saygılı, Uğur; Soytürk, Müjde; Karaca, Nurtac; Batur, Yücel; Uslu, Turhan; Erten, Oktay

doi:10.1006/gyno.2001.6575

Cited by 91 publications

(77 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Assessment of the serum level of CA125 has been widely used in the diagnosis of ovarian cancer (41). High serum CA125 levels have been associated with FIGO stage, but predominantly with serous histology, low-grade cancer cases and the presence of ascites (42)(43)(44)(45). Patients with CA125 levels >100 U/l were demonstrated to have shorter OS compared with patients with CA125 levels ≤100 U/l (46).…”

Section: Discussionmentioning

confidence: 99%

Expression of miR-146a in patients with ovarian cancer and its clinical significance

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Expression of miR-146a in patients with ovarian cancer and its clinical significance

et al. 2017

View full text Add to dashboard Cite

“…Serum CA125 concentrations are commonly raised in patients with PMP, and at initial presentation, may mimic gynaecological malignancies (Pranesh et al, 2005). However, it is noteworthy that serum CA125 levels may also be raised in conditions including peritoneal irritation (Sjovall et al, 2002), pelvic inflammatory disease (Halila et al, 1986) and benign hepatic disease (Topalak et al, 2002). Although our study demonstrated elevated levels of all three markers in one-third of the cases at baseline, and reductions of 50% or more in half of these, there was no relationship between treatment response and decrease in marker level.…”

Section: Discussionmentioning

confidence: 99%

A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei

et al. 2008

View full text Add to dashboard Cite

Pseudomyxoma peritonei (PMP) is a rare neoplastic process characterised by progressive intra-abdominal dissemination of mucinous tumour, and generally considered resistant to systemic chemotherapy. A phase II study in patients with advanced unresectable PMP was undertaken to evaluate the combination of systemic concurrent mitomycin C (7 mg m À2 i.v. on day 1) and capecitabine (1250 mg m À2 b.d. on days 1 -14) in a 3-weekly cycle (MCap). Response was determined by semiquantitative assessment of disease volume on serial computed tomographic (CT) scans and serum tumour marker (CEA, CA125, CA19-9) changes at 12 weeks. Between 2003 and 2006, 40 patients were recruited through a national centre for the treatment of peritoneal surface tumours. At baseline, 23 patients had progressive disease and 17 had stable disease. Of 39 assessable patients, 15 (38%, 95% confidence intervals (CIs): 25, 54%) benefited from chemotherapy in the form of either reductions in mucinous deposition or stabilisation of progressive pretreatment disease determined on CT scan. Notably, two patients, originally considered unresectable, following MCap and re-staging underwent potentially curative cytoreductive surgery. Grade 3/4 toxicity rates were low (6%, 95% CIs: 4, 9%). Twenty out of 29 assessed patients (69%, 95% CIs: 51, 83%) felt that their Global Health Status improved during chemotherapy. This is the first trial to demonstrate an apparent benefit of systemic chemotherapy in patients with advanced unresectable PMP.

show abstract

“…With regard to ovarian cancer, almost 80% of cases exhibit elevated serum CA-125 levels, but the specificity of this measurement is insufficient for the diagnosis (11,13). A recent report described an association between increased KL-6 levels and ovarian cancer, therefore, KL-6 is a useful tumor marker for ovarian cancer (14).…”

Section: Discussionmentioning

confidence: 99%

Diagnosis of ovarian cancers using thoracoscopy: Three case reports and review of the literature

Nakao

Oguri

Miyazaki

et al. 2012

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Thoracoscopy is a useful method for diagnosing plural lesions. We diagnosed 3 cases of ovarian adenocarcinoma by thoracoscopy. All patients were middle-aged and elderly women. Initial examination revealed intrathoracic lesions including pleural effusion, but intraperitoneal lesions were unclear. In all cases, adequate samples of tumor cells obtained using thoracoscopy were used in the identification of tumor origin. Elevated serum levels of cancer antigen 125 (CA-125) and Krebs von den lungen-6 (KL-6) were observed in 2 of the 3 patients. Diagnoses of ovarian cancer were based on immunohistochemical examinations and clinical course. This report describes the diagnostic usefulness of thoracoscopy and serum KL-6 in cases of ovarian cancer with predominantly intrathoracic lesions. IntroductionThoracoscopy is a useful technique for diagnosing plural lesions, and it provides valuable information for identifying a cancer of an unknown primary origin (CUP) (1-3). The diagnostic procedure for the evaluation of CUP includes clinical and laboratory investigations, namely, imaging, endoscopy, pathology and tumor markers (4). In particular, in the work-up of a CUP patient with exudative pleural effusion, thoracoscopy is an established tool to aid diagnosis (5,6).Ovarian cancer with intrathoracic metastases is often accompanied by abdominal-related symptoms, and ovarian cancer cases with only thoracic lesions are rare (7-10). It is not uncommon to initially categorize these rare cases as CUP (4,9,10). Here, we report 3 cases of ovarian cancer with predominantly intrathoracic lesions, which were diagnosed by thoracoscopy. In addition, in these cases, we observed an association between the serum Krebs von den lungen-6 (KL-6) level and the state of the ovarian cancer. Case reportsCase 1. A 46-year-old woman was referred to our hospital with right pleural effusion on chest radiograph and computed tomography (CT) (Fig. 1A and B). Her chief complaints were coughing and exertional dyspnea. She underwent diagnostic thoracentesis and cytological examination of pleural effusion showed adenocarcinoma cells. We could not detect the origin of the adenocarcinoma on chest and abdominal CT, gastroscopy, physical examination and gynecological examination. Serological test revealed highly elevated levels of cancer antigen 125 (CA-125) (761.6 U/ml; normal <28) and KL-6 (6991 U/ml; normal <500). Thoracoscopy was performed under local anesthesia, and multiple small nodular lesions of parietal pleura were observed (Fig. 1C). Histopathological and immunohistochemical analyses of pleural lesions showed poorly differentiated adenocarcinoma originating in the ovary or endometrium; the lesion was positive for CA-125, cytokeratin (CK) 7, epithelial membrane antigen (EMA), and vimentin, and negative for thyroid transcription factor (TTF)-1, CK20, calretinin, carcinoembryonic antigen (CEA) and gross cystic disease fluid protein (GCDFP)-15 ( Fig. 1D and E). Magnetic resonance imaging (MRI) suggested the possibility of an ovarian tumor. She recei...

show abstract

Serum, Pleural Effusion, and Ascites CA-125 Levels in Ovarian Cancer and Nonovarian Benign and Malignant Diseases: A Comparative Study

Cited by 91 publications

References 22 publications

Expression of miR-146a in patients with ovarian cancer and its clinical significance

Expression of miR-146a in patients with ovarian cancer and its clinical significance

A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei

Diagnosis of ovarian cancers using thoracoscopy: Three case reports and review of the literature

Contact Info

Product

Resources

About